Healthcare: Investor Brad Loncar Breaks Down ASCO 2019's Winners and Loser

<div>Earlier this month, industry watchers gathered at the annual American Society of Clinical Oncology (ASCO) conference to discuss the latest research in the battle against cancer. In today's show, biotech investing expert Brad Loncar shares his key takeaways from the event, including must-hear insight into programs underway at Iovance Biotherapeutics, MacroGenics, and the biotech unicorn, Grail.</div> <p><strong>Check out more of our content here:</strong></p> <ul> <li><a href= "https://www.fool.com/podcasts/?utm_source=podcasts&utm_medium=podcasts&utm_campaign=industryfocus" target="_blank" rel="noopener">TMF's podcast portal</a></li> <li><a href="https://www.youtube.com/user/TheMotleyFool" target= "_blank" rel="noopener">YouTube</a></li> <li><a href="https://twitter.com/mfindustryfocus?lang=en" target= "_blank" rel="noopener">Twitter</a></li> <li><a href="https://m.facebook.com/groups/217114601988296">Join Our Motley Fool Podcast Facebook Group</a></li> <li><a href= "https://www.linkedin.com/company/the-motley-fool">LinkedIn</a></li> <li><a href= "https://www.fool.com/ecap/the_motley_fool/stock-up/?aid=9205&source=isusitsz0000002&ftm_cam=stockup&ftm_veh=sidebarhelp&ftm_mes=signup"> StockUp, The Motley Fool's weekly email newsletter</a></li> </ul>